Clinical Trial Update: A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating TAK-079 as a single-agent subcutaneous therapy for relapsed/refractory multiple myeloma completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• TAK-079

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Relapsed/Refractory, Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-02-24